Bioventix PLC (LON:BVXP)‘s stock had its “corporate” rating reiterated by investment analysts at FinnCap in a report released on Monday. They currently have a GBX 2,600 ($34.18) target price on the biotechnology company’s stock. FinnCap’s price objective would suggest a potential downside of 5.97% from the company’s previous close.

Shares of Bioventix PLC (LON BVXP) opened at 2765.00 on Monday. The stock has a 50 day moving average price of GBX 2,584.21 and a 200-day moving average price of GBX 2,066.42. Bioventix PLC has a 12-month low of GBX 1,250.00 and a 12-month high of GBX 2,950.00. The stock’s market cap is GBX 140.27 million.

ILLEGAL ACTIVITY WARNING: This story was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at

About Bioventix PLC

Bioventix PLC is a United Kingdom-based biotechnology company. The principal activity of the Company is the development and supply of antibodies. The Company specializes in the development of sheep monoclonal antibodies (SMAs) for use in immunodiagnostics focusing on the areas of clinical diagnostics and drugs of abuse testing.

Receive News & Stock Ratings for Bioventix PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventix PLC and related stocks with our FREE daily email newsletter.